New test more effective at predicting survival in blood cancer patients

May 10, 2017 by Henry Winter

Technology that can detect the length of small DNA structures in cancer cells could hold the key to predicting the outcome of patients with two different types of blood cancer. The test, used in conjunction with current methods, may help doctors make better choices about the most appropriate and effective treatment option for individual patients.

Researchers from Cardiff University's School of Medicine showed that measuring sections of DNA called telomeres is a highly accurate indicator of how disease will progress in patients with the bone marrow cancer myeloma and pre-leukaemia myelodysplastic syndromes (MDS) – a bone marrow disorder often leading to life threatening and even acute myeloid leukaemia (AML).

Results from two studies, which were funded by the charities Bloodwise and Cancer Research UK, are published in new papers in the British Journal of Haematology.

The Cardiff team analysed samples from 134 myeloma patients, 80 MDS patients and 95 AML patients to see whether influences survival in these blood cancers.

Telomeres are protective stretches of DNA that cap the end of chromosomes, and act like plastic tips on shoelaces preventing chromosome ends from fraying and sticking to each other. Every time a cell divides the telomeres gradually shorten and eventually leave the chromosome ends exposed, triggering large-scale DNA damage that accelerates cancer progression and drug resistance.

After extracting chromosomes from the patients' cells, the researchers measured length in each sample using a technology they had previously developed called Single Telomere Length Analysis (STELA). Telomere length was then checked against patients' medical records to analyse its impact on disease progression and survival.

Currently, patients with myeloma are assessed at diagnosis as 'good', 'standard' and 'high' risk, based on age, overall health and levels of specific proteins in the blood and certain chromosomal abnormalities. The risk categories are used to provide guidance on the intensity of treatment needed for each patient and also indicate survival times. Patients with MDS have a similar assessment, based on chromosomal changes and through an analysis of blood cells in the .

The researchers found that while the current system was generally a good indicator of survival times, telomere length had a significant independent impact on survival.

Myeloma patients who had a 'good' or 'standard' risk score under the current system, but had short telomeres, had the same average survival times as patients in the 'high risk' group who had long, functional telomeres. A total of 55 percent of patients who had long telomeres in the 'good' or 'standard' risk groups lived for over 16 years, compared to just 21 percent of patients in these risk groups who had short telomeres.

Most of the patients with MDS in this study were judged to be 'low risk' under standard assessment, and had only received treatment to control their symptoms. In common with patients with myeloma, the researchers found that differing rates of telomere erosion had a clear impact on survival. Only 7 percent of MDS patients with short telomeres survived for more than eight years compared with 46 percent of patients with long telomeres.

Professor Duncan Baird, who led the research at Cardiff University's School of Medicine with Professors Chris Fegan and Chris Pepper, said: "We really need to improve the way we predict how an individual patient's myeloma or MDS will behave, as these conditions can vary widely in outcome. Our research provides strong evidence that shortening of telomeres plays a vital role in the progression of these blood cancers and that a significant number of patients should be receiving different levels of treatment. The next step is to assess telomere length in larger studies to establish how it can be integrated into existing assessments that predict patient outcome."

The researchers found that while patients with AML had significantly shorter telomeres than with MDS, whether telomeres where shorter or longer than the functioning threshold did not appear to lead to any significant differences in survival times.

Explore further: Telomere length predicts cancer risk

More information: Thet Thet Lin et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease, British Journal of Haematology (2014). DOI: 10.1111/bjh.13023

Related Stories

Telomere length predicts cancer risk

April 3, 2017
The length of the telomere "caps" of DNA that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute (UPCI) scientists will report ...

New test predicts survival in blood cancer patients

July 9, 2014
(Medical Xpress)—Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukaemia.

Study provides insights on chronic lung disease

June 15, 2015
A new study shows that shorter telomeres—which are the protective caps at the end of a cell's chromosomes—are linked with worse survival in a progressive respiratory disease called idiopathic pulmonary fibrosis (IPF). ...

$89 test kit claims to determine how well your cells are aging. Does it work?

November 28, 2016
A new $89 test claims to calculate the age of the DNA in your cells and tell you how well you are aging. The test, called TeloYears, is the newest in a bunch of mail-order kits that measure the length of telomeres, the caps ...

Scientists discover master regulator of cellular aging

January 12, 2017
Scientists at The Scripps Research Institute (TSRI) have discovered a protein that fine-tunes the cellular clock involved in aging.

Telomere length is indicator of blood count recovery in treatment of Acute Myeloid Leukemia

June 30, 2016
The chemotherapy treatments necessary to treat Acute Myeloid Leukemia (AML) in children can be grueling on the body, and can cause health-related complications during therapy, as well as long down the road after remission. ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.